Wedbush Weighs in on AnaptysBio’s Q4 Earnings (NASDAQ:ANAB)

AnaptysBio, Inc. (NASDAQ:ANAB) – Equities researchers at Wedbush issued their Q4 2026 earnings per share (EPS) estimates for AnaptysBio in a research note issued to investors on Thursday, August 7th. Wedbush analyst D. Nierengarten forecasts that the biotechnology company will earn ($0.84) per share for the quarter. Wedbush has a “Outperform” rating and a $45.00 price target on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($6.08) per share.

Several other brokerages also recently issued reports on ANAB. JPMorgan Chase & Co. upped their price target on AnaptysBio from $42.00 to $80.00 and gave the stock an “overweight” rating in a report on Thursday, July 24th. HC Wainwright upgraded AnaptysBio from a “neutral” rating to a “buy” rating and raised their target price for the stock from $22.00 to $38.00 in a research note on Wednesday, June 4th. Finally, Guggenheim reaffirmed a “buy” rating and issued a $90.00 price target (up previously from $54.00) on shares of AnaptysBio in a report on Wednesday, May 28th. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, AnaptysBio presently has an average rating of “Moderate Buy” and an average price target of $47.75.

AnaptysBio Stock Up 3.2%

NASDAQ ANAB opened at $21.03 on Friday. The business has a 50 day moving average price of $24.19 and a 200-day moving average price of $20.47. AnaptysBio has a 52 week low of $12.21 and a 52 week high of $41.31. The company has a market cap of $588.78 million, a price-to-earnings ratio of -4.69 and a beta of -0.20.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.50) by $0.16. The firm had revenue of $22.26 million for the quarter, compared to analyst estimates of $11.55 million. AnaptysBio had a negative return on equity of 366.98% and a negative net margin of 107.66%.

Institutional Investors Weigh In On AnaptysBio

Several hedge funds have recently made changes to their positions in ANAB. First Light Asset Management LLC raised its stake in AnaptysBio by 433.3% during the first quarter. First Light Asset Management LLC now owns 4,633,602 shares of the biotechnology company’s stock valued at $86,139,000 after buying an additional 3,764,720 shares during the last quarter. Fairmount Funds Management LLC bought a new position in shares of AnaptysBio in the fourth quarter worth about $24,050,000. Boxer Capital Management LLC bought a new position in shares of AnaptysBio in the fourth quarter worth about $17,212,000. Sanofi purchased a new stake in shares of AnaptysBio in the fourth quarter worth about $10,882,000. Finally, Soleus Capital Management L.P. purchased a new stake in shares of AnaptysBio in the fourth quarter worth about $5,481,000.

Insider Buying and Selling at AnaptysBio

In other news, Director Hollings Renton sold 20,925 shares of AnaptysBio stock in a transaction that occurred on Wednesday, July 2nd. The stock was sold at an average price of $23.57, for a total value of $493,202.25. Following the sale, the director directly owned 4,965 shares in the company, valued at approximately $117,025.05. This trade represents a 80.82% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 33.50% of the company’s stock.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.